Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

October 31, 2004

Study Completion Date

September 30, 2005

Conditions
Cancer
Interventions
BIOLOGICAL

recombinant human thrombopoietin

DRUG

carboplatin

DRUG

etoposide

DRUG

ifosfamide

BIOLOGICAL

G-CSF

Trial Locations (24)

6001

Princess Margaret Hospital for Children, Perth

10016

Kaplan Cancer Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

10032

Herbert Irving Comprehensive Cancer Center, New York

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

53792

University of Wisconsin Comprehensive Cancer Center, Madison

55455

University of Minnesota Cancer Center, Minneapolis

55905

Mayo Clinic Cancer Center, Rochester

64108

Children's Mercy Hospital - Kansas City, Kansas City

77030

University of Texas - MD Anderson Cancer Center, Houston

84132

Huntsman Cancer Institute, Salt Lake City

90806

Long Beach Memorial Medical Center, Long Beach

91010

Beckman Research Institute, City of Hope, Los Angeles

92668

Children's Hospital of Orange County, Orange

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

90027-0700

Children's Hospital Los Angeles, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20010-2970

Children's National Medical Center, Washington D.C.

46202-5265

Indiana University Cancer Center, Indianapolis

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

45229-3039

Children's Hospital Medical Center - Cincinnati, Cincinnati

37232-6838

Vanderbilt Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00003597 - Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter